Industry Bulletins | September 7, 2018
Otsuka Inks Collaboration Deal To Bring Abilify Mycite Drug-Device Combo To United States
Otsuka Pharmaceutical (Otsuka) recently announced it is forming a collaborative deal with Magellan Health to distribute its Abilify Mycite drug-device combination in the United States. Abilify Mycite is a prescription medicine for the treatment of schizophrenia, bipolar l disorder, and major depressive disorder.
With the collaboration, Abilify Mycite—the first FDA-approved drug-device combo with the ability to track drug ingestion—will now be able to have its drug tracking data transferred to Magellan Health’s mental health provider network. According to statements from Otsuka leadership, this will provide crucial insights for consumers and their health care providers . . .